|
|||||
|
|
Harnessing adaptive natural killer cells in cancer immunotherapy |
|
| Authors: | Lisa L. Liu Aline Pfefferle Vincent Oei Yi Sheng Andreas T. Bj?rklund Vivien Béziat Jodie P. Goodridge Karl-Johan Malmberg |
| Affiliation: | 1.Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden; 2.The KG Jebsen Center for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Norway; 3.Institute for Cancer Research, Oslo University Hospital, Norway; 4.Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Paris, France; 5.University Paris Descartes, Imagine Institute, Paris, France |
| Abstract: | Natural killer (NK) cells are innate lymphocytes with a refined ability to recognize transformed cells through a broad array of activating receptors in combination with stochastically expressed inhibitory receptors that recognize MHC‐class I. Recent advances in NK cell biology have revealed a high degree of functional plasticity that can be attributed to dynamic cell‐to‐cell interactions in concert with transcriptional and epigenetic reprogramming. Here, we discuss how new insights into the adaptive behavior of NK cells pave the way for next generation cell therapy based on guided differentiation and selective expansion of particularly cytotoxic NK cell subsets. |
| Keywords: | NK cells Immunotherapy Killer cell immunoglobulin-like receptors NKG2C Adaptive |